News & Updates
Stay informed with the latest Pharma News from curated sources
15 articles
Pharma industry warns minimum import prices plan could raise drug prices, hurt MSMEs
Pharma experts have flagged concerns over the government’s plan to set minimum import prices (MIP) for key drug ingredients such as Penicillin-G, 6APA and amoxicillin. They warn this will raise manufacturing costs, increase medicine prices and hurt over 10,000 MSMEs, potentially causing major job losses.
Read moreGovernment’s scheme to promote research and innovation evokes a massive response: Official
A month after the Department of Pharmaceutical (DoP) invited applications for research and innovation projects under its Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP) scheme, an initiative to transform the sector into a globally competitive, innovation-driven sector, 700 applications have been received by the department so far.
Read moreWhiteOak, Siguler & Creador to invest over Rs 1,000 cr in La Renon Healthcare
An investor consortium including WhiteOak Capital Management, Siguler Guff, and Creador has acquired approximately 10% of La Renon Healthcare for $1.2 billion. This deal involves stake dilution by promoters and existing investors, with Creador taking a significant portion. The valuation reflects a substantial jump since previous funding rounds.
Read moreBiocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-Shaw
Biocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to accelerate growth in the biologics space. The company is uniquely positioned with interchangeable biosimilar insulins and aims to capitalize on the growing GLP-1 market, bolstered by its acquisition of Viatris' biosimilars business.
Read moreHyderabad Police Bust $250 mln cyber-intimidation racket targeting drug maker Hetero Group
Hyderabad police have uncovered a sophisticated cyber-intimidation scheme. Perpetrators demanded a massive ransom from a Hetero Group employee. They threatened to share false information with the USFDA. This led to serious reputational and regulatory risks for the company. Police have arrested two individuals in connection with the racket.
Read moreQuality issues: Regulator looks to tighten marketing & sale of drugs
India's drug regulator plans new rules for medicine marketers. Companies will need a license to sell and distribute drugs. This aims to improve drug quality and safety. The move will impact domestic and multinational firms. It is expected to help curb fake medicines. The regulator seeks to create a database of marketers for better oversight.
Read moreEli Lilly wants to be part of making a big dent in obesity and diabetes, says co's India head Winselow Tucker
Eli Lilly India chief Winselow Tucker said the company’s strategy of combining a strong product with ecosystem partnerships and patient education has helped drive early momentum for Mounjaro in India, where the dual-action diabetes and obesity drug has clocked ₹450 crore in sales within seven months. He said India has a large unmet need, with nearly 100 million people living with obesity and diabetes, and that tirzepatide’s dual GIP and GLP-1 mechanism has set it apart in both weight and glucose management.
Read moreNovo Nordisk India prioritises patient outcomes; revenue growth follows naturally, says Shrotriya
Novo Nordisk India head Vikrant Shrotriya revealed a strategic 37% price cut for obesity drug Wegovy, aiming for wider accessibility. The company is preparing for semaglutide patent expiry next year by focusing on trust, quality, and education, mirroring its successful insulin strategy. Ozempic is slated for launch within three months, with pricing to be determined by market research.
Read moreAfter cough syrup deaths, drug regulator moves to tighten rules on high-risk solvents; unlicensed village pharmacies also under scrutiny
India's drug regulator is taking action after children died from contaminated cough syrups. They are looking into how to check the quality of ingredients like propylene glycol. The regulator is also considering stopping unlicensed pharmacists from selling cough syrups in villages. Experts are being consulted on whether to replace propylene glycol in these medicines.
Read moreEli Lilly get nod from CDSCO for it Alzheimer’s drug Donanemab
Eli Lilly has secured marketing authorization from India's CDSCO for its Alzheimer's drug, donanemab. This new disease-modifying therapy targets amyloid plaques, offering a significant milestone in addressing the urgent needs of early-stage Alzheimer's patients in India. The drug aims to slow cognitive decline, providing more time and improved quality of life for individuals and their families.
Read morePatent expiry looms: Eli Lilly and Novo Nordisk strategise to defend their top obesity drugs in India
At a recent industry summit, executives from Eli Lilly and Novo Nordisk unveiled their game plan for tackling weight-loss medications in India. With the patent on semaglutide shortly expiring, both companies are zeroing in on competitive pricing and broadening their market presence while addressing the challenge posed by generic alternatives.
Read moreOTC morning-after pills to be sold in varying doses, with warning: Sources
Morning-after pills will continue to be available without a prescription. However, they will now feature a prominent boxed warning. This warning will clarify that these pills do not protect against STIs and advise against using them more than twice a month. Certain contraceptive drugs are being moved to Schedule K, ensuring easier access for the public.
Read moreImport price floor on cards for critical pharma inputs
India is setting a minimum import price for essential drug ingredients. This move aims to shield local manufacturers from cheap imports, particularly from China. The government is expanding this policy to include more raw materials. This initiative supports India's goal of becoming self-reliant in pharmaceutical production. The new rules will soon be announced.
Read morePfizer launches new medication for migraine treatment
In a significant breakthrough for migraine sufferers in India, Pfizer has launched Rimegepant ODT, an innovative oral tablet that dissolves on the tongue. This medication provides rapid pain relief lasting up to 48 hours without the need for water, helping individuals reclaim lost days due to debilitating headaches.
Read moreThree-day pharma industry event from Nov 25 to host global pharma leaders, exhibitors, investors
India's pharmaceutical industry total market size is projected to reach $130 billion by 2030 and an impressive $450 billion by 2047, highlighting the country's growing role as a global pharmaceutical powerhouse.
Read more15 articles
Recalled Baby Formula Still on Store Shelves as Botulism Cases Rise
FRIDAY, Nov. 21, 2025 — Health officials are warning parents that recalled ByHeart baby formula is still showing up on store shelves, even as lab tests confirm it was contaminated with dangerous bacteria tied to a growing botulism...
Read moreNew Approach Could Make Gene-Editing Treatments Faster and Cheaper
FRIDAY, Nov. 21, 2025 — A new gene-editing strategy may one day help many people with rare genetic diseases. In a new study published Wednesday in the journal Nature, researchers say this new approach could make future treatments easier and...
Read moreHealth Experts Alarmed After CDC Revises Autism Webpage
FRIDAY, Nov. 21, 2025 — The U.S. Centers for Disease Control and Prevention (CDC) has updated a webpage about vaccines and autism, changing language that for years clearly stated there is no link between the two. The move has alarmed many...
Read moreNew Trial Shows Pfizer’s mRNA Flu Shot Beats Traditional Flu Vaccine
FRIDAY, Nov. 21, 2025 — Pfizer’s mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported. The results, published Nov. 19 in The New England Journal of Medicine, suggest that mRNA technology...
Read moreMost People Aren't Aware Of Genetic Risk For Dangerously High Cholesterol
FRIDAY, Nov. 21, 2025 — Most folks with genetics that put them at risk for high cholesterol and early heart disease aren’t aware of their danger, a new study says. Nearly 90% of people carrying genetics that cause dangerously high...
Read moreCompensation Claims More Frequently Rejected For Families Of Black Murder Victims
FRIDAY, Nov. 21, 2025 — Grieving families of Black murder victims are more likely to be denied their claims for victim compensation, a new study reports.These families are more likely to file for victim compensation following their loss, but face d...
Read moreCommon Health Problems Of Old Age Pose More Danger Following Major Surgery, Experts Say
FRIDAY, Nov. 21, 2025 — Common health problems of old age — dehydration, delirium, malnutrition or falls — can become catastrophic if they occur following a major surgery, a new study reports. Seniors who suffer these issues while...
Read moreThree Times As Many Lung Cancer Deaths Could Be Prevented With One Simple Step
FRIDAY, Nov. 21, 2025 — Three times as many lung cancer deaths could be prevented if everyone eligible for screening got a chest CT scan, a new study says. Only about 1 in 5 U.S. adults eligible for lung cancer screening received it in 2024...
Read morePopularity of Psilocybin, Psychedelics Hasn't Increased ER Visits
FRIDAY, Nov. 21, 2025 — Increased use of hallucinogens like psilocybin hasn’t created an increase in ER visits or hospitalizations for bad trips, researchers recently reported in JAMA Network Open. “In fact, after a small rise...
Read moreObesity No Barrier For Shoulder Replacement Surgery, Study Finds
FRIDAY, Nov. 21, 2025 — Obesity shouldn’t be considered a barrier for a patient who needs shoulder replacement surgery, a new study argues. In some places, doctors have been denying joint replacement surgery to people with a high...
Read moreNew Flu Variant Could Bring Another Severe U.S. Season
THURSDAY, Nov. 20, 2025 — A new flu variant spreading overseas may set the stage for another tough winter in the United States, experts warn. The strain, called subclade K, has caused a rise in flu cases in the United Kingdom, Canada and...
Read moreWhooping Cough Surges Nationwide as Vaccinations Fall
THURSDAY, Nov. 20, 2025 — Whooping cough is making a major comeback in the United States, with sharp increases now seen in Texas, Florida, California, Oregon and many other places. Health officials say the latest rise in pertussis cases is...
Read moreNearly Half of Americans Fear They Can’t Afford Care in 2026, Poll Finds
THURSDAY, Nov. 20, 2025 — Many Americans are bracing for higher medical costs in the new year and a growing number say those expenses are already shaping their decisions for care, according to a new survey. The latest West Health–Gallup...
Read moreScientists Say Kissing Began Long Before Humans Existed
THURSDAY, Nov. 20, 2025 — Kissing may feel like a very human habit, but new research suggests it has much deeper roots. A team of scientists says the behavior likely began more than 20 million years ago, long before modern humans...
Read moreU.S. Making No Progress In Protecting Pregnancy Health, March Of Dimes Report Card Says
THURSDAY, Nov. 20, 2025 — The United States has received another barely passing pregnancy health grade from the March of Dimes after another year in which 1 out of 10 babies were born prematurely. It’s the fourth consecutive year the...
Read more10 articles
Strategic Planning in Motion: The Hidden Accelerator in Drug Development
Strategic Planning in Motion: The Hidden Accelerator in Drug Development
Biopharma teams are under growing pressure to advance assets faster, navigate rising complexity and make earlier decisions with greater confidence. Download the infographic to explore the strategies that are reshaping early-stage development and driving stronger outcomes across the pipeline.
There's a faster path to CDx test commercialization
There's a faster path to CDx test commercialization
Explore a faster, more efficient path to commercializing your companion diagnostic. This infographic shows how you can accelerate development, reduce delays, and reach the right patients sooner. Download this infographic to learn more.
Bridging Gaps in the Patient Journey: How E-Prescribing Can Drive Smarter Access and Engagement Strategies
Bridging Gaps in the Patient Journey: How E-Prescribing Can Drive Smarter Access and Engagement Strategies scox
For today’s life sciences leaders, ensuring patients can access and stay on therapy requires more than compelling messaging—it demands understanding into the prescribing journey. Yet many brand and patient access leaders still face barriers when it comes to getting patients on medication—market access and patient engagement strategies are imperative for patient success.
Join this webinar to explore how e-prescribing and interoperable health data are reshaping the pharmaceutical landscape and examine how these connections open new opportunities for life sciences organizations to streamline communication, support safer prescribing, and strengthen the patient journey.
In this webinar, you’ll learn how to:
- Understand the full e-prescribing ecosystem and how connectivity drives efficiency, safety, and access across the healthcare landscape
- Explore innovative strategies to identify barriers to patient access and uncover new opportunities to improve adherence
- Create more consistent, informed, and personalized engagement across channels with e-prescribing insights for brand and patient support functions,
- Drive alignment between marketing and patient access functions, ensuring patients receive the right information and support at every step of the therapy journey
This discussion will give brand and patient access leaders the clarity they need to better understand how prescribing decisions are made—and how to use that knowledge to deliver a more connected, patient-centered experience.
How to bring clinical trial financial management in-house: Balancing technology and expertise
How to bring clinical trial financial management in-house: Balancing technology and expertise jpiatt
Read moreRedefining the Future of Autoimmune Kidney Disease: The Central Role of BAFF and APRIL
Redefining the Future of Autoimmune Kidney Disease: The Central Role of BAFF and APRIL pesurya
Read moreRevolutionize the Future of Precision Oncology with Breakthrough Epigenomic Biomarkers
Revolutionize the Future of Precision Oncology with Breakthrough Epigenomic Biomarkers
Genomics-only testing leaves many patients behind. Download this free white paper to see how epigenomic biomarkers can improve patient stratification and accelerate precision oncology.
Reaching the next level for RWE applications in pharma
Reaching the next level for RWE applications in pharma
As AI reshapes how pharma uses real-world evidence, companies are finding new ways to accelerate insights and strengthen data governance. Download this free white paper to discover next-generation RWE applications, emerging AI capabilities, and best practices for managing data responsibly.
Navigating the New Era of Pharma Compliance
Navigating the New Era of Pharma Compliance scox
The pharmaceutical landscape is entering a pivotal era of transformation. With the Inflation Reduction Act’s Maximum Fair Price (MFP) provisions coming into force, the HRSA 340B pilot redefining compliance benchmarks, and broader political and economic forces influencing pharma today, manufacturers must stay informed to prepare for revenue management impacts.
Join our panel of industry experts as they unpack the evolving policy landscape, executive actions, and market dynamics that are redefining pharma revenue management and compliance. This session will equip you with the insights and foresight needed to stay ahead of change.
We’ll discuss:
- Policy in Motion: Evolving regulations and pricing frameworks—and what they mean for the industry
- Political & Economic Drivers: How government actions and market forces are shaping the healthcare landscape
Gain clarity on where U.S. pharma policy is headed—and what steps your organization can take now to strengthen compliance, manage risk, and protect revenue integrity.
Harnessing Timely Patient Voice: Strategies For Optimizing Clinical Research Design
Harnessing Timely Patient Voice: Strategies For Optimizing Clinical Research Design
Incorporating patient voice into clinical trial design improves recruitment, consent, and retention while helping trials meet goals efficiently. Download now to learn how sponsors can capture patient insights effectively and optimize clinical research design.
Solve Trial Complexity with Earlier, Patient-centered Laboratory Engagement Strategies
Solve Trial Complexity with Earlier, Patient-centered Laboratory Engagement Strategies pesurya
As clinical trials become more complex and geographically expansive, sponsors face a growing challenge: how to effectively balance scientific rigor, operational efficiency, and the patient experience.
This rising complexity demands a shift in mindset—one that reimagines study design and stakeholder engagement. Join this session to explore why integrating central labs early in the protocol development process is key to unlocking speed, quality, and scalability across studies. You’ll learn about the latest strategies for ensuring your organization keeps pace with scientific innovation while also improving outcomes for patients.
Discussion highlights include:
How to rethink protocol design through early lab collaboration
Approaches for reducing variability and operational friction across global sites
Ways to advance data quality, consistency, and real-time decision-making
Actionable ideas for balancing innovation with patient-centric trial delivery
A guide to building transparent, adaptable sponsor-lab partnerships for long-term success